SlideShare a Scribd company logo
1 of 33
BREAST CANCER
Overview
● Breast cancer is the second most common carcinoma in females.
● Second to lung cancer as a cause of death
● Etiology of vast majority is unknown
● Now, the mortality rate is decreasing owing to early detection
● Surgery is considered as primary treatment for ca breast
Risk factors
● More common in developed countries
● More common after middle age, females.
● Attaining early menarche and late menopause.
● Nulliparity
● Late first child birth (>35 years)
● Obesity
● Li- Fraumen’s syndrome (90%), Cowden syndrome (50%)
● Previous therapeutic radiation ( thoracic)
● Hormone replacement therapy more than 5 years
● Alcoholism
● 2-5%cases are familial, majority are sporadic.
● BRCA1 mutation (long arm of chromosome 17)- high risk of breast
carcinoma, commonly shows ER negative status, more aggressive
tumors with poor prognosis.
● BRCA2 mutation (long arm of chromosome 13)- usually shows ER
positive status with good prognosis.
● Both genes are associated with high risk of ovarian cancer.
● Occasionally BRCA3 and p53 suppressor gene is also involved.
● Risk is 3-5 times more if 1st degree relative is having breast cancer.
● Carcinoma in one breast increases the risk of developing carcinoma in
opposite breast by 3-4 times.
Protective factors
● Early first child birth
● Breast feeding
● Vitamin C reduces risk
Pathology
● Breast carcinoma arising from lactiferous ducts is called as DUCTAL
CARCINOMA.
● Breast carcinoma arising from lobules is called LOBULAR
CARCINOMA.
● IN SITU CARCINOMA is a preinvasive carcinoma which has not
breached the epithelial membrane, INVASIVE CARCINOMA can
occur eventually.
● Invasive carcinoma arises through a series of molecular changes at
cellular level resulting in outgrowth and spread of breast epithelial
cells with immortal features and uncontrolled growth.
CLASSIFICATION
Ductal carcinoma In Situ (DCIS)
● It is intraductal carcinoma without any invasion into basement membrane.
● High grade- SOLID, COMEDO
● Low grade- CRIBRIFORM, PAPILLARY
● Untreated DCIS becomes invasive in >50% cases
● Invasive ductal carcinoma forms in the same breast and the same quadrant of DCIS unlike LCIS .
● Nipple discharge and small swellings are main presentations.
● Investigations- US assisted FNAC and mammography
Management
● FNAC confirms the disease but will not differentiate from DCIS and invasive carcinoma
● Mammography. US breast, MRI breast
● Routine metastatic work up
● Breast conservative surgery with RT to breast and axillary dissection after SLNB (If +ve)
● Hormone therapy (tamoxifen) prevents both local recurrence and development of new
primary breast carcinoma
● Total mastectomy is done in DCIS when-positive margin after wide local excision; two or
more primary tumour (multicentric); when radiation to breast is not possible (collagen
diseases); tumour/breast size ratio is not appropriate for conservative surgery, diffuse
microcalcifications, family history and DCIS in pregnancy.
● Skin sparing mastectomy (SSM) may be ideal in such occasions with immediate
TRAM/LD flap.
Types of carcinoma breast
1. Scirrhous carcinoma
2. Medullary carcinoma
3. Inflammatory / lactating / mastitis carcinomatosis
4. Colloid carcinoma
5. Paget’s disease of nipple
6. Atrophic scirrhous carcinoma
7. Lobular carcinoma in situ
Biological behaviour and clinical features of
carcinoma breast
PRESENTATIONS:
● Lump in the breast which is hard, painless (most common). At least
tumour should become 1 cm to clinically palpable
● Nipple discharge is the second common presentation
● Ulceration and fungation
● Axillary lymph node enlargement, supraclavicular lymph node
enlargement
● Chest pain and haemoptysis
● Bone pain, tenderness, and pathological fracture
● Pleural effusion, ascites
● Liver secondaries, secondary ovarian tumour
● Pain in the lump in 10% cases
● Most common site is upper outer quadrant
● Cutaneous manifestations:
● Peau d'orange- orange peel appearance due to obstruction of
dermal lymphatics
● Dimpling of skin due to infiltration of ligament of Cooper
Peau d’orange
LYMPHATIC SPREAD- occurs through
● Subareolar sappey’s lymphatic plexus
● Cutaneous lymphatics
● Inflammatory lymphatics
Groups 1st and 2nd are commonly involved.
Spread restricted to level1 nodes carry better prognosis.
TNM staging of carcinoma breast
Stage groups
MOLECULAR SUBTYPES
INVESTIGATIONS OF CARCINOMA BREAST
Clinical examination
1. History
This should include the following elements:
• breast mass
• breast pain
● nipple discharge
• nipple or skin retraction
• axillary mass or pain
• arm swelling
● symptoms of possible metastatic spread
2. Past medical history of breast disease in detail.
3. Family history of breast and other cancers with
emphasis on gynaecological cancers. 4. Reproductive history:
age at menarche
age at first delivery number of pregnancies, children and
miscarriages
age at onset of menopause
history of hormonal viz OCP/HRT
5. Past medical history.
4. Local examination:
• breast mass
- size
-location (specified by clock position and distance from the
edge of the areola)
-shape - consistency
-fixation to skin, pectoral muscle and chest wall
- multiplicity
• skin changes
- erythema (location and extent) - oedema (location and extent)
- dimpling
- infiltration -ulceration - satellite nodules
nipple changes
-retraction
- erythema
- erosion and ulceration
-discharge (specify)
• nodal status -axillary nodes on both sides (number, size, location and fixation
to other nodes
or underlying structures) -supraclavicular nodes
.local examination of possible metastatic sites.
IMAGING- MAMMOGRAPHY
Mammography is a special type of low-dose (0.1 cGy per study) x-ray imaging used to
create detailed images of the breast.
Mammography can demonstrate microcalcifications smaller than 100 um;
• Reveals a lesion, 1-2 years before it is palpable by BSE.
● Each chest roentgenogram delivers one quarter of this radiation volume
● Not a substitute for biopsy; rather is an adjunctive
● two films are taken- craniocaudal and mediolateral
● INDICATIONS-
1. Screening- beyond 40years age.
2. Diagnostic- to evaluate existing symptoms of breast disease or in patient who had
breast conservative surgery earlier.
3. Obese patients
4. Whenever conservative breast surgeries are planned
5. spread / de novo tumor in opposite breast
6. Mammography guided biopsy
7. Follow up mammography after surgery
Findings- mammography
● Mass- size, location, margin
● Microcalcifications
● Microcalcifications
● Spiculations, Duct distortions
IMAGING- Ultrasound
INDICATIONS
● Age less than 40 years
● Differentiate between solid and cystic tumors
● Pregnant woman with lump
● Young women with dense breast
IMAGING- MRI
INDICATIONS-
● Women with breast implants
● Differentiate between multifocal and multicentric lumps
● Most sensitive for DCIS
Investigation of choice for local scar recurrence
● In a person with suspected ductal lesion and inconclusive USG
● Screening modality for young and high risk patients
HISTOPATHOLOGY
● Fine needle aspiration cytology
● Fine needle non aspiration cytology
● Trucut biopsy
● Excisional biopsy
MANAGEMENT
1. SURGICAL
2. CHEMOTHERAPY
3. RADIOTHERAPY
4. HORMONOTHERAPY.

More Related Content

Similar to BREAST CANCERpart1.pptx

Breast Carcinoma pakistan.pptx
Breast Carcinoma pakistan.pptxBreast Carcinoma pakistan.pptx
Breast Carcinoma pakistan.pptxJawad Awan
 
4 u1.0-b978-1-4160-6643-9..00193-4..docpdf
4 u1.0-b978-1-4160-6643-9..00193-4..docpdf4 u1.0-b978-1-4160-6643-9..00193-4..docpdf
4 u1.0-b978-1-4160-6643-9..00193-4..docpdfLoveis1able Khumpuangdee
 
CARCINOMA OF THE BREAST for mbbs 600L students
CARCINOMA OF THE BREAST for mbbs 600L studentsCARCINOMA OF THE BREAST for mbbs 600L students
CARCINOMA OF THE BREAST for mbbs 600L studentsIgbashio
 
keyword-Free main keyword for cancer
keyword-Free main keyword for cancerkeyword-Free main keyword for cancer
keyword-Free main keyword for cancerFulchan Ali
 
BREAST CANCER_074427.pptx
BREAST CANCER_074427.pptxBREAST CANCER_074427.pptx
BREAST CANCER_074427.pptxShubhrimaKhan
 
Uterine sarcoma presentation (ibanda and ongala)
Uterine sarcoma presentation (ibanda and ongala)Uterine sarcoma presentation (ibanda and ongala)
Uterine sarcoma presentation (ibanda and ongala)hood ibanda
 
opening the door of palliative care for breast cancer patient
opening the door of palliative care for breast cancer patientopening the door of palliative care for breast cancer patient
opening the door of palliative care for breast cancer patientEmran PK
 
4. Cellular Aberration
4. Cellular Aberration   4. Cellular Aberration
4. Cellular Aberration Abigail Abalos
 
Intraoperative radiotherapy carcinoma breast
Intraoperative radiotherapy carcinoma breastIntraoperative radiotherapy carcinoma breast
Intraoperative radiotherapy carcinoma breastAbhishek Thakur
 

Similar to BREAST CANCERpart1.pptx (20)

Breast ca
Breast  ca Breast  ca
Breast ca
 
Breast Carcinoma pakistan.pptx
Breast Carcinoma pakistan.pptxBreast Carcinoma pakistan.pptx
Breast Carcinoma pakistan.pptx
 
TUMOUR OF THE BREAST
TUMOUR OF THE BREASTTUMOUR OF THE BREAST
TUMOUR OF THE BREAST
 
Ca endometrium
Ca endometriumCa endometrium
Ca endometrium
 
Breast Cancer
Breast CancerBreast Cancer
Breast Cancer
 
Breast diseases
Breast diseasesBreast diseases
Breast diseases
 
4 u1.0-b978-1-4160-6643-9..00193-4..docpdf
4 u1.0-b978-1-4160-6643-9..00193-4..docpdf4 u1.0-b978-1-4160-6643-9..00193-4..docpdf
4 u1.0-b978-1-4160-6643-9..00193-4..docpdf
 
Gynecology 5th year, 7th lecture/part two (Dr. Sindus)
Gynecology 5th year, 7th lecture/part two (Dr. Sindus)Gynecology 5th year, 7th lecture/part two (Dr. Sindus)
Gynecology 5th year, 7th lecture/part two (Dr. Sindus)
 
CARCINOMA OF THE BREAST for mbbs 600L students
CARCINOMA OF THE BREAST for mbbs 600L studentsCARCINOMA OF THE BREAST for mbbs 600L students
CARCINOMA OF THE BREAST for mbbs 600L students
 
Breast cancer.
Breast cancer.Breast cancer.
Breast cancer.
 
keyword-Free main keyword for cancer
keyword-Free main keyword for cancerkeyword-Free main keyword for cancer
keyword-Free main keyword for cancer
 
Carcinoma breast dr mnr
Carcinoma breast dr mnrCarcinoma breast dr mnr
Carcinoma breast dr mnr
 
BREAST CANCER_074427.pptx
BREAST CANCER_074427.pptxBREAST CANCER_074427.pptx
BREAST CANCER_074427.pptx
 
Carcinoma breast clinical pathology dr mnr
Carcinoma breast clinical pathology dr mnrCarcinoma breast clinical pathology dr mnr
Carcinoma breast clinical pathology dr mnr
 
Breast cancer
Breast cancerBreast cancer
Breast cancer
 
Gyne.ppt
Gyne.pptGyne.ppt
Gyne.ppt
 
Uterine sarcoma presentation (ibanda and ongala)
Uterine sarcoma presentation (ibanda and ongala)Uterine sarcoma presentation (ibanda and ongala)
Uterine sarcoma presentation (ibanda and ongala)
 
opening the door of palliative care for breast cancer patient
opening the door of palliative care for breast cancer patientopening the door of palliative care for breast cancer patient
opening the door of palliative care for breast cancer patient
 
4. Cellular Aberration
4. Cellular Aberration   4. Cellular Aberration
4. Cellular Aberration
 
Intraoperative radiotherapy carcinoma breast
Intraoperative radiotherapy carcinoma breastIntraoperative radiotherapy carcinoma breast
Intraoperative radiotherapy carcinoma breast
 

Recently uploaded

Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfJayanti Pande
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxiammrhaywood
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxVishalSingh1417
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxVishalSingh1417
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactdawncurless
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingTeacherCyreneCayanan
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin ClassesCeline George
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfAyushMahapatra5
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdfQucHHunhnh
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17Celine George
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfChris Hunter
 
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...KokoStevan
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphThiyagu K
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAssociation for Project Management
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterMateoGardella
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.MateoGardella
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxDenish Jangid
 

Recently uploaded (20)

Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
Mattingly "AI & Prompt Design: Structured Data, Assistants, & RAG"
 
Web & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdfWeb & Social Media Analytics Previous Year Question Paper.pdf
Web & Social Media Analytics Previous Year Question Paper.pdf
 
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptxSOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
SOCIAL AND HISTORICAL CONTEXT - LFTVD.pptx
 
Unit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptxUnit-IV- Pharma. Marketing Channels.pptx
Unit-IV- Pharma. Marketing Channels.pptx
 
Unit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptxUnit-IV; Professional Sales Representative (PSR).pptx
Unit-IV; Professional Sales Representative (PSR).pptx
 
Accessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impactAccessible design: Minimum effort, maximum impact
Accessible design: Minimum effort, maximum impact
 
fourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writingfourth grading exam for kindergarten in writing
fourth grading exam for kindergarten in writing
 
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17  How to Extend Models Using Mixin ClassesMixin Classes in Odoo 17  How to Extend Models Using Mixin Classes
Mixin Classes in Odoo 17 How to Extend Models Using Mixin Classes
 
Class 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdfClass 11th Physics NEET formula sheet pdf
Class 11th Physics NEET formula sheet pdf
 
1029 - Danh muc Sach Giao Khoa 10 . pdf
1029 -  Danh muc Sach Giao Khoa 10 . pdf1029 -  Danh muc Sach Giao Khoa 10 . pdf
1029 - Danh muc Sach Giao Khoa 10 . pdf
 
How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17How to Give a Domain for a Field in Odoo 17
How to Give a Domain for a Field in Odoo 17
 
Making and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdfMaking and Justifying Mathematical Decisions.pdf
Making and Justifying Mathematical Decisions.pdf
 
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
SECOND SEMESTER TOPIC COVERAGE SY 2023-2024 Trends, Networks, and Critical Th...
 
Advance Mobile Application Development class 07
Advance Mobile Application Development class 07Advance Mobile Application Development class 07
Advance Mobile Application Development class 07
 
Z Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot GraphZ Score,T Score, Percential Rank and Box Plot Graph
Z Score,T Score, Percential Rank and Box Plot Graph
 
APM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across SectorsAPM Welcome, APM North West Network Conference, Synergies Across Sectors
APM Welcome, APM North West Network Conference, Synergies Across Sectors
 
Gardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch LetterGardella_PRCampaignConclusion Pitch Letter
Gardella_PRCampaignConclusion Pitch Letter
 
Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.Gardella_Mateo_IntellectualProperty.pdf.
Gardella_Mateo_IntellectualProperty.pdf.
 
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptxBasic Civil Engineering first year Notes- Chapter 4 Building.pptx
Basic Civil Engineering first year Notes- Chapter 4 Building.pptx
 
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptxINDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
INDIA QUIZ 2024 RLAC DELHI UNIVERSITY.pptx
 

BREAST CANCERpart1.pptx

  • 2. Overview ● Breast cancer is the second most common carcinoma in females. ● Second to lung cancer as a cause of death ● Etiology of vast majority is unknown ● Now, the mortality rate is decreasing owing to early detection ● Surgery is considered as primary treatment for ca breast
  • 3. Risk factors ● More common in developed countries ● More common after middle age, females. ● Attaining early menarche and late menopause. ● Nulliparity ● Late first child birth (>35 years) ● Obesity ● Li- Fraumen’s syndrome (90%), Cowden syndrome (50%) ● Previous therapeutic radiation ( thoracic) ● Hormone replacement therapy more than 5 years ● Alcoholism
  • 4. ● 2-5%cases are familial, majority are sporadic. ● BRCA1 mutation (long arm of chromosome 17)- high risk of breast carcinoma, commonly shows ER negative status, more aggressive tumors with poor prognosis. ● BRCA2 mutation (long arm of chromosome 13)- usually shows ER positive status with good prognosis. ● Both genes are associated with high risk of ovarian cancer. ● Occasionally BRCA3 and p53 suppressor gene is also involved. ● Risk is 3-5 times more if 1st degree relative is having breast cancer. ● Carcinoma in one breast increases the risk of developing carcinoma in opposite breast by 3-4 times.
  • 5.
  • 6. Protective factors ● Early first child birth ● Breast feeding ● Vitamin C reduces risk
  • 7. Pathology ● Breast carcinoma arising from lactiferous ducts is called as DUCTAL CARCINOMA. ● Breast carcinoma arising from lobules is called LOBULAR CARCINOMA. ● IN SITU CARCINOMA is a preinvasive carcinoma which has not breached the epithelial membrane, INVASIVE CARCINOMA can occur eventually. ● Invasive carcinoma arises through a series of molecular changes at cellular level resulting in outgrowth and spread of breast epithelial cells with immortal features and uncontrolled growth.
  • 8.
  • 10. Ductal carcinoma In Situ (DCIS) ● It is intraductal carcinoma without any invasion into basement membrane. ● High grade- SOLID, COMEDO ● Low grade- CRIBRIFORM, PAPILLARY ● Untreated DCIS becomes invasive in >50% cases ● Invasive ductal carcinoma forms in the same breast and the same quadrant of DCIS unlike LCIS . ● Nipple discharge and small swellings are main presentations. ● Investigations- US assisted FNAC and mammography
  • 11.
  • 12. Management ● FNAC confirms the disease but will not differentiate from DCIS and invasive carcinoma ● Mammography. US breast, MRI breast ● Routine metastatic work up ● Breast conservative surgery with RT to breast and axillary dissection after SLNB (If +ve) ● Hormone therapy (tamoxifen) prevents both local recurrence and development of new primary breast carcinoma ● Total mastectomy is done in DCIS when-positive margin after wide local excision; two or more primary tumour (multicentric); when radiation to breast is not possible (collagen diseases); tumour/breast size ratio is not appropriate for conservative surgery, diffuse microcalcifications, family history and DCIS in pregnancy. ● Skin sparing mastectomy (SSM) may be ideal in such occasions with immediate TRAM/LD flap.
  • 13. Types of carcinoma breast 1. Scirrhous carcinoma 2. Medullary carcinoma 3. Inflammatory / lactating / mastitis carcinomatosis 4. Colloid carcinoma 5. Paget’s disease of nipple 6. Atrophic scirrhous carcinoma 7. Lobular carcinoma in situ
  • 14. Biological behaviour and clinical features of carcinoma breast PRESENTATIONS: ● Lump in the breast which is hard, painless (most common). At least tumour should become 1 cm to clinically palpable ● Nipple discharge is the second common presentation ● Ulceration and fungation ● Axillary lymph node enlargement, supraclavicular lymph node enlargement ● Chest pain and haemoptysis ● Bone pain, tenderness, and pathological fracture ● Pleural effusion, ascites ● Liver secondaries, secondary ovarian tumour ● Pain in the lump in 10% cases
  • 15. ● Most common site is upper outer quadrant ● Cutaneous manifestations: ● Peau d'orange- orange peel appearance due to obstruction of dermal lymphatics ● Dimpling of skin due to infiltration of ligament of Cooper Peau d’orange
  • 16. LYMPHATIC SPREAD- occurs through ● Subareolar sappey’s lymphatic plexus ● Cutaneous lymphatics ● Inflammatory lymphatics Groups 1st and 2nd are commonly involved. Spread restricted to level1 nodes carry better prognosis.
  • 17. TNM staging of carcinoma breast
  • 18.
  • 19.
  • 23. Clinical examination 1. History This should include the following elements: • breast mass • breast pain ● nipple discharge • nipple or skin retraction • axillary mass or pain • arm swelling ● symptoms of possible metastatic spread
  • 24. 2. Past medical history of breast disease in detail. 3. Family history of breast and other cancers with emphasis on gynaecological cancers. 4. Reproductive history: age at menarche age at first delivery number of pregnancies, children and miscarriages age at onset of menopause history of hormonal viz OCP/HRT 5. Past medical history.
  • 25. 4. Local examination: • breast mass - size -location (specified by clock position and distance from the edge of the areola) -shape - consistency -fixation to skin, pectoral muscle and chest wall - multiplicity • skin changes - erythema (location and extent) - oedema (location and extent) - dimpling - infiltration -ulceration - satellite nodules
  • 26. nipple changes -retraction - erythema - erosion and ulceration -discharge (specify) • nodal status -axillary nodes on both sides (number, size, location and fixation to other nodes or underlying structures) -supraclavicular nodes .local examination of possible metastatic sites.
  • 27. IMAGING- MAMMOGRAPHY Mammography is a special type of low-dose (0.1 cGy per study) x-ray imaging used to create detailed images of the breast. Mammography can demonstrate microcalcifications smaller than 100 um; • Reveals a lesion, 1-2 years before it is palpable by BSE. ● Each chest roentgenogram delivers one quarter of this radiation volume ● Not a substitute for biopsy; rather is an adjunctive ● two films are taken- craniocaudal and mediolateral ● INDICATIONS- 1. Screening- beyond 40years age. 2. Diagnostic- to evaluate existing symptoms of breast disease or in patient who had breast conservative surgery earlier. 3. Obese patients 4. Whenever conservative breast surgeries are planned 5. spread / de novo tumor in opposite breast 6. Mammography guided biopsy 7. Follow up mammography after surgery
  • 28. Findings- mammography ● Mass- size, location, margin ● Microcalcifications ● Microcalcifications ● Spiculations, Duct distortions
  • 29. IMAGING- Ultrasound INDICATIONS ● Age less than 40 years ● Differentiate between solid and cystic tumors ● Pregnant woman with lump ● Young women with dense breast
  • 30. IMAGING- MRI INDICATIONS- ● Women with breast implants ● Differentiate between multifocal and multicentric lumps ● Most sensitive for DCIS Investigation of choice for local scar recurrence ● In a person with suspected ductal lesion and inconclusive USG ● Screening modality for young and high risk patients
  • 31.
  • 32. HISTOPATHOLOGY ● Fine needle aspiration cytology ● Fine needle non aspiration cytology ● Trucut biopsy ● Excisional biopsy
  • 33. MANAGEMENT 1. SURGICAL 2. CHEMOTHERAPY 3. RADIOTHERAPY 4. HORMONOTHERAPY.